Non-viral vectors for gene therapy are non-viral vehicles (particle based or chemical based) that deliver the genetic material into a wide variety of cells, tissues and whole organs to treat or improve the health condition of the patient.
This report aims to provide a comprehensive presentation of the global market for Non-viral Vectors Gene Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-viral Vectors Gene Therapy. This report contains market size and forecasts of Non-viral Vectors Gene Therapy in global, including the following market information:
Global Non-viral Vectors Gene Therapy Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Non-viral Vectors Gene Therapy market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Oligonucleotides Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Non-viral Vectors Gene Therapy include Biogen, Sarepta Therapeutics, Gilead Sciences, Amgen, Novartis, Orchard Therapeutics, Spark Therapeutics, Agc Biologics and Anges, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Non-viral Vectors Gene Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-viral Vectors Gene Therapy Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Non-viral Vectors Gene Therapy Market Segment Percentages, by Type, 2022 (%)
Oligonucleotides
Other Non-viral Vectors
Global Non-viral Vectors Gene Therapy Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Non-viral Vectors Gene Therapy Market Segment Percentages, by Application, 2022 (%)
In Vivo
Ex Vivo
Global Non-viral Vectors Gene Therapy Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Non-viral Vectors Gene Therapy Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Non-viral Vectors Gene Therapy revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Non-viral Vectors Gene Therapy revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Biogen
Sarepta Therapeutics
Gilead Sciences
Amgen
Novartis
Orchard Therapeutics
Spark Therapeutics
Agc Biologics
Anges
Bluebird Bio
Jazz Pharmaceuticals
Dynavax Technologies
Outline of Major Chapters:
Chapter 1: Introduces the definition of Non-viral Vectors Gene Therapy, market overview.
Chapter 2: Global Non-viral Vectors Gene Therapy market size in revenue.
Chapter 3: Detailed analysis of Non-viral Vectors Gene Therapy company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Non-viral Vectors Gene Therapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Non-viral Vectors Gene Therapy Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Non-viral Vectors Gene Therapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Non-viral Vectors Gene Therapy Overall Market Size
2.1 Global Non-viral Vectors Gene Therapy Market Size: 2022 VS 2029
2.2 Global Non-viral Vectors Gene Therapy Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Non-viral Vectors Gene Therapy Players in Global Market
3.2 Top Global Non-viral Vectors Gene Therapy Companies Ranked by Revenue
3.3 Global Non-viral Vectors Gene Therapy Revenue by Companies
3.4 Top 3 and Top 5 Non-viral Vectors Gene Therapy Companies in Global Market, by Revenue in 2022
3.5 Global Companies Non-viral Vectors Gene Therapy Product Type
3.6 Tier 1, Tier 2 and Tier 3 Non-viral Vectors Gene Therapy Players in Global Market
3.6.1 List of Global Tier 1 Non-viral Vectors Gene Therapy Companies
3.6.2 List of Global Tier 2 and Tier 3 Non-viral Vectors Gene Therapy Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Non-viral Vectors Gene Therapy Market Size Markets, 2022 & 2029
4.1.2 Oligonucleotides
4.1.3 Other Non-viral Vectors
4.2 By Type - Global Non-viral Vectors Gene Therapy Revenue & Forecasts
4.2.1 By Type - Global Non-viral Vectors Gene Therapy Revenue, 2018-2023
4.2.2 By Type - Global Non-viral Vectors Gene Therapy Revenue, 2024-2029
4.2.3 By Type - Global Non-viral Vectors Gene Therapy Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Non-viral Vectors Gene Therapy Market Size, 2022 & 2029
5.1.2 In Vivo
5.1.3 Ex Vivo
5.2 By Application - Global Non-viral Vectors Gene Therapy Revenue & Forecasts
5.2.1 By Application - Global Non-viral Vectors Gene Therapy Revenue, 2018-2023
5.2.2 By Application - Global Non-viral Vectors Gene Therapy Revenue, 2024-2029
5.2.3 By Application - Global Non-viral Vectors Gene Therapy Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Non-viral Vectors Gene Therapy Market Size, 2022 & 2029
6.2 By Region - Global Non-viral Vectors Gene Therapy Revenue & Forecasts
6.2.1 By Region - Global Non-viral Vectors Gene Therapy Revenue, 2018-2023
6.2.2 By Region - Global Non-viral Vectors Gene Therapy Revenue, 2024-2029
6.2.3 By Region - Global Non-viral Vectors Gene Therapy Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Non-viral Vectors Gene Therapy Revenue, 2018-2029
6.3.2 US Non-viral Vectors Gene Therapy Market Size, 2018-2029
6.3.3 Canada Non-viral Vectors Gene Therapy Market Size, 2018-2029
6.3.4 Mexico Non-viral Vectors Gene Therapy Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Non-viral Vectors Gene Therapy Revenue, 2018-2029
6.4.2 Germany Non-viral Vectors Gene Therapy Market Size, 2018-2029
6.4.3 France Non-viral Vectors Gene Therapy Market Size, 2018-2029
6.4.4 U.K. Non-viral Vectors Gene Therapy Market Size, 2018-2029
6.4.5 Italy Non-viral Vectors Gene Therapy Market Size, 2018-2029
6.4.6 Russia Non-viral Vectors Gene Therapy Market Size, 2018-2029
6.4.7 Nordic Countries Non-viral Vectors Gene Therapy Market Size, 2018-2029
6.4.8 Benelux Non-viral Vectors Gene Therapy Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Non-viral Vectors Gene Therapy Revenue, 2018-2029
6.5.2 China Non-viral Vectors Gene Therapy Market Size, 2018-2029
6.5.3 Japan Non-viral Vectors Gene Therapy Market Size, 2018-2029
6.5.4 South Korea Non-viral Vectors Gene Therapy Market Size, 2018-2029
6.5.5 Southeast Asia Non-viral Vectors Gene Therapy Market Size, 2018-2029
6.5.6 India Non-viral Vectors Gene Therapy Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Non-viral Vectors Gene Therapy Revenue, 2018-2029
6.6.2 Brazil Non-viral Vectors Gene Therapy Market Size, 2018-2029
6.6.3 Argentina Non-viral Vectors Gene Therapy Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Non-viral Vectors Gene Therapy Revenue, 2018-2029
6.7.2 Turkey Non-viral Vectors Gene Therapy Market Size, 2018-2029
6.7.3 Israel Non-viral Vectors Gene Therapy Market Size, 2018-2029
6.7.4 Saudi Arabia Non-viral Vectors Gene Therapy Market Size, 2018-2029
6.7.5 UAE Non-viral Vectors Gene Therapy Market Size, 2018-2029
7 Non-viral Vectors Gene Therapy Companies Profiles
7.1 Biogen
7.1.1 Biogen Company Summary
7.1.2 Biogen Business Overview
7.1.3 Biogen Non-viral Vectors Gene Therapy Major Product Offerings
7.1.4 Biogen Non-viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.1.5 Biogen Key News & Latest Developments
7.2 Sarepta Therapeutics
7.2.1 Sarepta Therapeutics Company Summary
7.2.2 Sarepta Therapeutics Business Overview
7.2.3 Sarepta Therapeutics Non-viral Vectors Gene Therapy Major Product Offerings
7.2.4 Sarepta Therapeutics Non-viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.2.5 Sarepta Therapeutics Key News & Latest Developments
7.3 Gilead Sciences
7.3.1 Gilead Sciences Company Summary
7.3.2 Gilead Sciences Business Overview
7.3.3 Gilead Sciences Non-viral Vectors Gene Therapy Major Product Offerings
7.3.4 Gilead Sciences Non-viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.3.5 Gilead Sciences Key News & Latest Developments
7.4 Amgen
7.4.1 Amgen Company Summary
7.4.2 Amgen Business Overview
7.4.3 Amgen Non-viral Vectors Gene Therapy Major Product Offerings
7.4.4 Amgen Non-viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.4.5 Amgen Key News & Latest Developments
7.5 Novartis
7.5.1 Novartis Company Summary
7.5.2 Novartis Business Overview
7.5.3 Novartis Non-viral Vectors Gene Therapy Major Product Offerings
7.5.4 Novartis Non-viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.5.5 Novartis Key News & Latest Developments
7.6 Orchard Therapeutics
7.6.1 Orchard Therapeutics Company Summary
7.6.2 Orchard Therapeutics Business Overview
7.6.3 Orchard Therapeutics Non-viral Vectors Gene Therapy Major Product Offerings
7.6.4 Orchard Therapeutics Non-viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.6.5 Orchard Therapeutics Key News & Latest Developments
7.7 Spark Therapeutics
7.7.1 Spark Therapeutics Company Summary
7.7.2 Spark Therapeutics Business Overview
7.7.3 Spark Therapeutics Non-viral Vectors Gene Therapy Major Product Offerings
7.7.4 Spark Therapeutics Non-viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.7.5 Spark Therapeutics Key News & Latest Developments
7.8 Agc Biologics
7.8.1 Agc Biologics Company Summary
7.8.2 Agc Biologics Business Overview
7.8.3 Agc Biologics Non-viral Vectors Gene Therapy Major Product Offerings
7.8.4 Agc Biologics Non-viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.8.5 Agc Biologics Key News & Latest Developments
7.9 Anges
7.9.1 Anges Company Summary
7.9.2 Anges Business Overview
7.9.3 Anges Non-viral Vectors Gene Therapy Major Product Offerings
7.9.4 Anges Non-viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.9.5 Anges Key News & Latest Developments
7.10 Bluebird Bio
7.10.1 Bluebird Bio Company Summary
7.10.2 Bluebird Bio Business Overview
7.10.3 Bluebird Bio Non-viral Vectors Gene Therapy Major Product Offerings
7.10.4 Bluebird Bio Non-viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.10.5 Bluebird Bio Key News & Latest Developments
7.11 Jazz Pharmaceuticals
7.11.1 Jazz Pharmaceuticals Company Summary
7.11.2 Jazz Pharmaceuticals Business Overview
7.11.3 Jazz Pharmaceuticals Non-viral Vectors Gene Therapy Major Product Offerings
7.11.4 Jazz Pharmaceuticals Non-viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.11.5 Jazz Pharmaceuticals Key News & Latest Developments
7.12 Dynavax Technologies
7.12.1 Dynavax Technologies Company Summary
7.12.2 Dynavax Technologies Business Overview
7.12.3 Dynavax Technologies Non-viral Vectors Gene Therapy Major Product Offerings
7.12.4 Dynavax Technologies Non-viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.12.5 Dynavax Technologies Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Non-viral Vectors Gene Therapy Market Opportunities & Trends in Global Market
Table 2. Non-viral Vectors Gene Therapy Market Drivers in Global Market
Table 3. Non-viral Vectors Gene Therapy Market Restraints in Global Market
Table 4. Key Players of Non-viral Vectors Gene Therapy in Global Market
Table 5. Top Non-viral Vectors Gene Therapy Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Non-viral Vectors Gene Therapy Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Non-viral Vectors Gene Therapy Revenue Share by Companies, 2018-2023
Table 8. Global Companies Non-viral Vectors Gene Therapy Product Type
Table 9. List of Global Tier 1 Non-viral Vectors Gene Therapy Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Non-viral Vectors Gene Therapy Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Non-viral Vectors Gene Therapy Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Non-viral Vectors Gene Therapy Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application ? Global Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Non-viral Vectors Gene Therapy Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Non-viral Vectors Gene Therapy Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region ? Global Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Non-viral Vectors Gene Therapy Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Non-viral Vectors Gene Therapy Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2024-2029
Table 30. Biogen Company Summary
Table 31. Biogen Non-viral Vectors Gene Therapy Product Offerings
Table 32. Biogen Non-viral Vectors Gene Therapy Revenue (US$, Mn) & (2018-2023)
Table 33. Biogen Key News & Latest Developments
Table 34. Sarepta Therapeutics Company Summary
Table 35. Sarepta Therapeutics Non-viral Vectors Gene Therapy Product Offerings
Table 36. Sarepta Therapeutics Non-viral Vectors Gene Therapy Revenue (US$, Mn) & (2018-2023)
Table 37. Sarepta Therapeutics Key News & Latest Developments
Table 38. Gilead Sciences Company Summary
Table 39. Gilead Sciences Non-viral Vectors Gene Therapy Product Offerings
Table 40. Gilead Sciences Non-viral Vectors Gene Therapy Revenue (US$, Mn) & (2018-2023)
Table 41. Gilead Sciences Key News & Latest Developments
Table 42. Amgen Company Summary
Table 43. Amgen Non-viral Vectors Gene Therapy Product Offerings
Table 44. Amgen Non-viral Vectors Gene Therapy Revenue (US$, Mn) & (2018-2023)
Table 45. Amgen Key News & Latest Developments
Table 46. Novartis Company Summary
Table 47. Novartis Non-viral Vectors Gene Therapy Product Offerings
Table 48. Novartis Non-viral Vectors Gene Therapy Revenue (US$, Mn) & (2018-2023)
Table 49. Novartis Key News & Latest Developments
Table 50. Orchard Therapeutics Company Summary
Table 51. Orchard Therapeutics Non-viral Vectors Gene Therapy Product Offerings
Table 52. Orchard Therapeutics Non-viral Vectors Gene Therapy Revenue (US$, Mn) & (2018-2023)
Table 53. Orchard Therapeutics Key News & Latest Developments
Table 54. Spark Therapeutics Company Summary
Table 55. Spark Therapeutics Non-viral Vectors Gene Therapy Product Offerings
Table 56. Spark Therapeutics Non-viral Vectors Gene Therapy Revenue (US$, Mn) & (2018-2023)
Table 57. Spark Therapeutics Key News & Latest Developments
Table 58. Agc Biologics Company Summary
Table 59. Agc Biologics Non-viral Vectors Gene Therapy Product Offerings
Table 60. Agc Biologics Non-viral Vectors Gene Therapy Revenue (US$, Mn) & (2018-2023)
Table 61. Agc Biologics Key News & Latest Developments
Table 62. Anges Company Summary
Table 63. Anges Non-viral Vectors Gene Therapy Product Offerings
Table 64. Anges Non-viral Vectors Gene Therapy Revenue (US$, Mn) & (2018-2023)
Table 65. Anges Key News & Latest Developments
Table 66. Bluebird Bio Company Summary
Table 67. Bluebird Bio Non-viral Vectors Gene Therapy Product Offerings
Table 68. Bluebird Bio Non-viral Vectors Gene Therapy Revenue (US$, Mn) & (2018-2023)
Table 69. Bluebird Bio Key News & Latest Developments
Table 70. Jazz Pharmaceuticals Company Summary
Table 71. Jazz Pharmaceuticals Non-viral Vectors Gene Therapy Product Offerings
Table 72. Jazz Pharmaceuticals Non-viral Vectors Gene Therapy Revenue (US$, Mn) & (2018-2023)
Table 73. Jazz Pharmaceuticals Key News & Latest Developments
Table 74. Dynavax Technologies Company Summary
Table 75. Dynavax Technologies Non-viral Vectors Gene Therapy Product Offerings
Table 76. Dynavax Technologies Non-viral Vectors Gene Therapy Revenue (US$, Mn) & (2018-2023)
Table 77. Dynavax Technologies Key News & Latest Developments
List of Figures
Figure 1. Non-viral Vectors Gene Therapy Segment by Type in 2022
Figure 2. Non-viral Vectors Gene Therapy Segment by Application in 2022
Figure 3. Global Non-viral Vectors Gene Therapy Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Non-viral Vectors Gene Therapy Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Non-viral Vectors Gene Therapy Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Non-viral Vectors Gene Therapy Revenue in 2022
Figure 8. By Type - Global Non-viral Vectors Gene Therapy Revenue Market Share, 2018-2029
Figure 9. By Application - Global Non-viral Vectors Gene Therapy Revenue Market Share, 2018-2029
Figure 10. By Type - Global Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Non-viral Vectors Gene Therapy Revenue Market Share, 2018-2029
Figure 12. By Application - Global Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Non-viral Vectors Gene Therapy Revenue Market Share, 2018-2029
Figure 14. By Region - Global Non-viral Vectors Gene Therapy Revenue Market Share, 2018-2029
Figure 15. By Country - North America Non-viral Vectors Gene Therapy Revenue Market Share, 2018-2029
Figure 16. US Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Non-viral Vectors Gene Therapy Revenue Market Share, 2018-2029
Figure 20. Germany Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2029
Figure 21. France Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Non-viral Vectors Gene Therapy Revenue Market Share, 2018-2029
Figure 28. China Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2029
Figure 32. India Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Non-viral Vectors Gene Therapy Revenue Market Share, 2018-2029
Figure 34. Brazil Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Non-viral Vectors Gene Therapy Revenue Market Share, 2018-2029
Figure 37. Turkey Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2029
Figure 41. Biogen Non-viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Sarepta Therapeutics Non-viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Gilead Sciences Non-viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Amgen Non-viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Novartis Non-viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Orchard Therapeutics Non-viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Spark Therapeutics Non-viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Agc Biologics Non-viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Anges Non-viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Bluebird Bio Non-viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Jazz Pharmaceuticals Non-viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Dynavax Technologies Non-viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
